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Background: The interest of first- and second-line treatments in
non-small cell lung cancer (NSCLC) has been demonstrated by
successive randomized trials. Improvements in lung cancer care
have routinely allowed a significant proportion of patients to be
considered for third-line treatment.
Methods: A retrospective analysis was performed, including all
consecutive patients with advanced NSCLC, who received at least
three lines of systemic antineoplastic treatment at our institution.
Results: From a population of 613 patients treated with first-line
treatment, a total of 173 patients received third-line treatment
(cytotoxic chemotherapy in 131 patients; epidermal growth factor
(EGFR) tyrosine kinase inhibitors in 42 patients). Only 13 patients
(8%) received less than 75% of the theoretical dose intensity; 22
patients (13%) presented with severe toxicities. Symptom relief and
performance status (PS) improvement were observed in 121 (92% of
the 131 patients with symptoms) and 90 patients (52%), respec-
tively. Using multivariate analysis, survival after third-line treatment
was significantly increased in patients younger than 70 years-old
(hazard ratio [HR] 0.73, 95% confidence interval [CI]: 0.53–0.99,
p  0.047), who smoked less than 10 pack-years (HR  0.82, 95%
CI: 0.57–0.93, p 0.036), with no cancer-related symptoms (HR
0.75, 95% CI: 0.61–0.92, p  0.007), a weight loss inferior to 5 kg
since the beginning of second-line (HR  0.63, 95% CI: 0.52–0.75,
p 0.013), a PS 0 to 1 (HR 0.81, 95% CI: 0.76–0.86, p 0.008),
and no extrathoracic tumor spread at initiation of third-line treatment
(HR  0.67, 95% CI: 0.47–0.94, p  0.042). Disease control after
both first- and second-line treatments was the strongest predictor of
prolonged survival after third-line treatment (HR  0.47, 95% CI:
0.33–0.67, p  0.001).
Conclusions: Patients with advanced NSCLC may benefit from
third-line treatment. The best candidates can be identified using
standard prognostic factors, such as PS, and disease control after
first- and second-line treatments.
Key-Words: Non-small cell lung cancer, Advanced stage, Third-
line treatment, Chemotherapy, Tyrosine Kinase Inhibitor.
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Chemotherapy is the standard treatment of advanced non-small cell lung cancer (NSCLC).1–4 Two-drug, platinum-
based regimens with third-generation agents significantly
improve overall survival and quality of life.1,5 For second-line
treatment, three agents have been approved so far, based on
randomized phase III trials: two cytotoxic drugs, that is,
docetaxel and pemetrexed, and one targeted therapy, erlo-
tinib.6–8 These drugs, although providing a modest 1-year
survival benefit (ranging from 6 to 10%), significantly im-
prove quality of life and cancer-related symptoms.6–8 Erlo-
tinib is the only specifically approved agent for third-line
treatment, as half of the patients included in the landmark
trial comparing erlotinib with best supportive care had pre-
viously received two chemotherapy regimens.3,8 Interest-
ingly, a significant proportion of third-line patients, up to
35%, were also included in the second-line trials evaluating
docetaxel.6,9 Collectively, these studies showed the overall
benefit of single-agent treatment in the second-line setting
and beyond.
The clinical improvements provided by first- and sec-
ond-line treatment in NSCLC have led a higher proportion of
patients to be considered for third-line treatment, rising from
6% in 1990s10 to 26% after 2000.11 Meanwhile, more patients
are willing to receive treatment for lung cancer, especially if
quality of life improvements are likely to occur.12 Although a
survival benefit may also exist in some cases, the main aim of
third-line treatment should be palliation of symptoms, while
minimizing side effects.
As no prospective study specifically addressed the role
of third-line treatment in NSCLC, we conducted a retrospec-
tive analysis to determine which patients may benefit from
third-line treatment, using symptom relief, disease control,
and overall survival as major endpoints.
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MATERIALS AND METHODS
Study Population
We included all consecutive patients with NSCLC, who
received at least three lines of systemic antineoplastic treat-
ment between January 1, 2000 and December 31, 2006 in the
Department of Respiratory Medicine and Thoracic Oncology
of the University Hospital of Besanc¸on, France. All chemo-
therapy treatments were administered in this single outpatient
clinic, using standardized guidelines. Patients were identified
using the pharmacy database. Inclusion criteria were: (1) patho-
logically proven primary NSCLC (adenocarcinoma, squamous
cell carcinoma, or large cell carcinoma)13; (2) American Joint
Committee on Cancer stage IIIB or IV at time of diagnosis14; (3)
treatment with systemic antineoplastic drugs (cytotoxic chemo-
therapy or epidermal growth factor receptor [EGFR] tyrosine
kinase inhibitors [TKIs]); (4) without any focal treatment on the
lung tumor, at any time of the therapeutic management; and (5)
administration of at least one course of third-line treatment. We
excluded from the analysis patients with any previous history
of invasive malignancy. As per standard recommendations,
third-line treatment was initiated only at the time of progres-
sion after second-line treatment. All patients experiencing
recurrence or progression after second-line treatment and in a
sufficient medical condition to receive another line of treat-
ment were treated with third-line treatment. All patients had
a subsequent follow-up in our department.
Clinical Review
A retrospective review of the clinical history of eligible
patients was performed. According to French laws, such
analyses do not require the approval of an institutional review
board. At time of initial diagnosis, all cases had been assessed
with a complete history, physical examination, fiberoptic
bronchoscopy, imaging investigations (chest radiography and
computed tomography [CT]; brain CT-scan or magnetic res-
onance imaging; abdomen ultrasound or CT-scan; and bone
scintigraphy in some patients), pathologic reports, and blood
tests results. Progression or recurrence after second-line treat-
ment was usually diagnosed using CT-scan of the chest and
of target lesions when appropriate. Patients were categorized
as never smokers (less than 100 lifetime cigarettes), former
smokers (quit more than 1 year ago), or current smokers (quit
less than 1 year ago). Duration of first-, second-, and third-
line treatment was calculated from the first to the last day of
treatment. Best response to chemotherapy was evaluated
according to the World Health Organization criteria.15 Dis-
ease control rate was defined as the addition of objective
response and stabilization rates. Chemotherapy dose intensity
was calculated as the following: (total administered dose,
mg/m2/wk)/(theoretical total dose, mg/m2/wk), for the first
four planned cycles.16 Toxicities were assessed using the
National Cancer Institute grading system.17
Cancer-Related Symptoms
Cancer-related symptoms and Eastern Cooperative On-
cology Group performance status (PS) were systematically
evaluated and routinely recorded for every patient visit to the
clinic. For this study, we collected the presence or absence of
each of the following cancer-related manifestations before
and along the duration of third-line treatment: dyspnea, chest
pain, cough, hemoptysis, fever, thrombosis, metastasis-re-
lated pain, para-neoplastic disease, cachexia, and fatigue.
Statistical Analyses
All patients were included in the statistical calculations.
Follow-up was obtained in all cases and was censored on
December 31, 2008. Categorical variables were compared using
the 2 test and continuous variables by the Mann-Whitney
nonparametric test. Logistic regression was used to study corre-
lations between disease control after first-, second-, and third-
line treatment. Survival was assessed using the Kaplan-Meier
method.18 Relevant parameters were studied for influence on
survival by univariate analysis using the log rank test and by
multivariate analysis using a stepwise Cox proportional hazards
method (entry and exit, p  0.10). Results were considered
significant at the 0.05 level. Statistical analyses were performed
using the SPSS software program (Chicago, IL), version 17.0.
RESULTS
Study Population
A total of 173 patients received third-line treatment during
the study period, what corresponds to 28% of the 613 patients
with unresectable stage IIIB or IV NSCLC treated with first-line
chemotherapy (Fig. 1). Baseline characteristics of these 173
FIGURE 1. Study population.
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patients are presented in Table 1. The first two lines of treatment
mostly consisted of chemotherapy, as per the standard recom-
mendations at time of the study (Table 2). First-line treatment
was a platinum-based doublet in 142 patients (82%), and second
line was single-agent chemotherapy (mostly docetaxel, gemcit-
abine, or pemetrexed) in 156 patients (90%).
Third-Line Treatment Characteristics
Third-line treatment was cytotoxic chemotherapy for
131 patients (76%) and EGFR TKIs for 42 patients (24%;
Table 2). Chemotherapy consisted of a single agent for 125
patients (72%). Most frequently administered drugs were
gemcitabine (62 patients), docetaxel (30 patients), and pem-
etrexed (20 patients). Third-line treatment was different from
that delivered as first- and second-line treatment for all patients.
Median duration of third-line treatment was 2.1 months (95%
CI: 1.9–2.2 months), when compared with 3.3 months (95% CI:
3.0–3.6 months) and 2.3 months (95% CI: 2.1–2.5 months), for
first- and second-line treatments, respectively (p  0.534).
Third-line treatment was highly feasible as 127 patients
(73%) received at least 90% of the theoretical dose intensity.
Only 13 patients (8%) received less than 75% of the theoret-
ical dose intensity. Only 22 patients (13%) presented with
grade 3 to 4 acute toxicities (Table 2), including hematolog-
TABLE 1. Baseline Characteristics of the Study Population
Characteristics n %
Total 173 100
Gender
Male 128 74
Female 45 26
Age at diagnosis
70 yr 129 75
70 yr 44 25
Smoking characteristics
Smoking status
Current smoker 75 43
Former smoker 72 42
Never smoker 26 15
Smoking quantity
10 pack-years 32 18
10 pack-years 141 82
Tumor characteristics
Histology
Adenocarcinoma 110 64
Squamous cell carcinoma 38 22
Large-cell carcinoma 25 14
Staginga
Tumor
T1 13 8
T2 67 39
T3 17 10
T4 76 44
Nodal
N0 34 20
N1 21 12
N2 43 25
N3 75 43
Metastasis
M0 52 30
M1 121 70
a As of Ref. 14.
TABLE 2. Characteristics of First-, Second-,
and Third-Line Treatment
Third-Line
Treatment
First-Line
Treatment
Second-Line
Treatment
n 100% n 100% n 100%
Total 173 100 173 100 173 100
Patient characteristics
at day 1
Performance status
0–1 88 51 150 87 130 75
2 85 49 23 13 43 25
Loss of weight since
previous line
5 kg 139 80 N/A N/A 131 76
5 kg 34 20 N/A N/A 42 24
Treatment
Regimen
Tripleta 0 0 8 5 0 0
Doublet
Platinum based 3 2 142 82 12 7
Nonplatinum based 3 2 4 2 1 1
Single-agent
chemotherapy
125 72 19 11 156 90
Docetaxel 32 18 1 1 62 36
Pemetrexed 20 12 0 0 46 27
Gemcitabine 62 36 8 5 43 25
Vinorelbine 2 1 6 3 2 2
Paclitaxel 9 5 3 2 3 2
Tyrosine kinase
inhibitor
42 24 1 1 4 2
Number of cycles
1–2 45 26 31 18 60 35
3–4 51 29 83 48 64 37
5–6 35 20 48 28 30 17
6 0 0 10 6 15 9
N/Ab 42 24 1 1 4 2
Grade III–IV acute
toxicities
Hematological 17 10 18 10 8 5
Digestive 16 9 7 4 1 1
Neuropathy 9 5 7 4 1 1
Hepatic 1 1 2 1 0 0
Renal 0 0 1 1 0 0
Others 18 10 5 3 3 2
Tumor control
Complete response 0 0 6 3 0 0
Partial response 10 6 66 38 24 14
Stabilization 52 30 62 36 52 30
Progression 111 64 39 23 97 56
a Combination of cisplatinum, ifosfamide, and vinorelbine.
b Not applicable for patients who received tyrosine kinase inhibitors.
N/A, not applicable.
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ical complications in 10 cases, febrile neutropenia in 7 cases,
digestive disorders in 16 cases, and neuropathy in 9 cases.
Severe toxicity rate was similar in patients receiving chemo-
therapy or TKIs (13 and 12%, respectively). Treatment was
discontinued following severe toxicity in 15 patients (9%), 10
of whom had completed more than four cycles of third-line
chemotherapy or 3 months of treatment for EGFR TKIs.
Treatment discontinuation rate was not statistically different
in patients receiving chemotherapy or TKIs (8 and 10%,
respectively).
Cancer-Related Symptoms Relief and PS
Improvement
Of the 173 patients, 131 (76%) had cancer-related
symptoms at initiation of third-line treatment. Most frequent
symptoms included dyspnea (76 patients), chest pain (62
patients), thromboembolic disease (32 patients), cough (31
patients), metastasis-related pain (25 patients), and hemopty-
sis (20 patients). Partial or complete symptom relief was
observed in 121 patients (92%) during third-line treatment. In
the 59 patients who became completely asymptomatic, initial
symptoms consisted of dyspnea (26 patients), chest pain (18
patients), cough (16 patients), and hemoptysis (16 patients).
Even if PS was 0 to 1 for 88 patients (51%) at initiation
of third-line treatment (Table 2), PS improvement of at least
1 point was observed in 90 patients (52%). PS was stable in
additional 69 patients (40%).
Disease Control
Disease control rate after third-line treatment was 36%,
which was significantly lower than after first- and second-line
treatments (77 and 44%, respectively; p  0.001; Table 2).
Disease control after third-line treatment was significantly
associated with disease control after second-line treatment
(hazard ratio [HR]  2.51, 95% confidence interval [CI]:
1.32–4.65, p  0.006), but not after first-line treatment
(HR  1.83, 95% CI: 0.81–4.13, p  0.135).
TABLE 3. Significant Prognostic Factors on Overall Survival from the Initiation of Third-Line Treatment
Univariate Analysis Multivariate Analysis
Median
Survival (mo)
Hazard
Ratio 95% CI p
Hazard
Ratio 95% CI p
Patient characteristics
Gender
Female 6.5 0.73 0.51–1.05 0.092 0.72 0.50–1.04 0.113
Male 4.9 1 1
Initial tumor stage
IIIB 6.0 0.96 0.68–1.35 0.811 0.99 0.80–2.38 0.767
IV 5.8 1 1
Histology
Adenocarcinoma 6.0 0.65 0.68–1.27 0.649 0.84 0.61–1.15 0.263
Others 5.1 1 1
Smoking history
10 pack-year 11.9 0.55 0.36–0.84 0.003 0.82 0.57–0.93 0.036
10 pack-year 5.0 1 1
Characteristics at initiation of third-line treatment
Age
70 yr 8.8 0.72 0.53–0.98 0.034 0.73 0.53–0.99 0.047
70 yr 4.9 1 1
Symptoms at initiation of third-line treatment
No 6.9 0.53 0.37–0.76 0.001 0.75 0.61–0.92 0.007
Yes 4.1 1 1
Weight loss since the end of second-line treatment
5 kg 11.8 0.61 0.53–0.81 0.001 0.63 0.52–0.75 0.013
5 kg 4.0 1 1
Performance status at initiation of third-line treatment
0–1 6.0 0.62 0.52–0.75 0.001 0.81 0.76–0.86 0.008
2–3 3.2 1 1
Absence of extra-thoracic tumor lesion
Yes 6.9 0.64 0.46–0.89 0.007 0.67 0.47–0.94 0.042
No 4.6 1 1
Response to previous treatments
Disease control after first- and second-line 10.3 0.45 0.32–0.62 0.001 0.47 0.33–0.67 0.001
Progression after first- and/or second-line 4.0 1 1
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Overall Survival
At the time of analysis, all 173 patients were dead (169
from tumor progression and 4 from intercurrent disease).
Overall median, 6-, and 12-month survival from first-line
treatment were 16.4 months, 93 and 69%, respectively. Me-
dian, 6-, and 12-month survival after third-line treatment
were 5.8 months, 47, and 25%, respectively. Survival after
third-line treatment was higher than 3 months in 121 patients
(70%) and higher than 6 months in 83 patients (48%).
Results of univariate analysis are presented in Table 3.
The following variables were included in the multivariate
analysis: gender, smoking history, weight loss, PS, presence
of extrathoracic tumor spread, response to first- and second-
line treatment. Survival after third-line treatment was signif-
icantly increased in patients less than 70-years old (HR 
0.73, 95% CI: 0.53–0.99, p  0.047), who had smoked less
than 10 pack-years (HR  0.82, 95% CI: 0.57–0.93, p 
0.036), with no cancer-related symptoms (HR  0.75, 95%
CI: 0.61–0.92, p  0.007), a weight loss less than 5 kg since
the beginning of the second line (HR  0.63, 95% CI:
0.52–0.75, p  0.013), a PS of 0 to 1 (HR  0.81, 95% CI:
0.76–0.86, p  0.008), and no extrathoracic tumor spread at
initiation of third-line treatment (HR  0.67, 95% CI: 0.47–
0.94, p  0.042; Table 3). Disease control after first- and
second-line treatments was the strongest predictor of pro-
longed survival after third-line treatment (HR  0.47, 95%
CI: 0.33–0.67, p  0.001; Table 3, Fig. 2).
DISCUSSION
This study is the largest reported series of patients who
were given third-line chemotherapy for advanced NSCLC.
Our analysis showed that third-line treatment was highly
feasible in the selected population, as 73% of patients re-
ceived at least 90% of the theoretical dose intensity and less
than 10% experienced severe toxicity leading to discontinue
the treatment. Third-line treatment led to symptom relief and
PS control in more than 90% of patients. Disease control was
achieved in 36% of patients. Survival after third-line treat-
ment was significantly longer in case of disease control after
both first- and second-line treatment.
In this study, third-line treatment was delivered to
nearly 30% of patients with advanced NSCLC. Patients who
are considered for third-line treatment definitely represent a
selected population of advanced NSCLC with better progno-
sis. In our cohort, baseline PS was 0 to 1 in 87% of cases
(Table 1), what is one of the strongest prognostic factors in
NSCLC.19 Second, response rate to first-line treatment (41%)
and overall survival from diagnosis (16.4 months) were
nearly twice the ones observed in patients included in ran-
domized trials with doublet chemotherapy (20% and 7.9
months, respectively, in the study reported by Schiller et al5).
Finally, a significant proportion (55%) of patients had no
extrathoracic tumor spread at time of diagnosis, a favorable
prognostic factor recently identified in the Lung Cancer
Staging Project analysis.20
In our study, the clinical benefit from third-line treat-
ment was striking, as PS was stable or increased in 92% of
patients and cancer-related symptoms relief was obtained in
more than 90% of patients during treatment. As the majority
of patients had symptoms when third-line treatment was
considered, this may represent a better end point than re-
sponse rate, which, as expected, was lower than after the first
two lines. Regarding survival, nearly half of our patients were
alive more than 6 months after the initiation of third-line
treatment, which suggests that third-line treatment may serve
as a salvage treatment after second-line treatment for a
significant proportion of patients.21 Interestingly, we did not
identify any differences between chemotherapy and EGFR
TKIs regarding response rate and survival.
Finally, despite its limitations (retrospective design and
single institution recruitment) our study may help the deci-
sion making when facing a patient with advanced NSCLC
presenting with tumor progression after second-line treat-
ment. Our analysis showed that well-recognized favorable
prognostic factors identified for first-line chemotherapy were
still relevant for third-line treatment: age less than 70 years,
PS 0 to 1, the absence of cancer-related symptoms and weight
loss,19,22 a short smoking history,23 and the absence of ex-
trathoracic metastases.20 Interestingly, survival benefit after
third-line treatment was strongly associated with disease
control after the first two lines of treatment. Such association
has previously been suggested for second-line treatment us-
ing docetaxel and pemetrexed.24 For clinical practice, our
analysis suggests that patients whose tumor was never con-
trolled by previous treatments may not be good candidates for
conventional third-line treatment.
FIGURE 2. Overall survival from the initiation of third-line
treatment, according to disease control after first- and sec-
ond-line treatment. Median survival was 10.3 months in
case of disease control after first- and second-line treatment
and 4.0 months in case of progression after first- and/or
second-line treatment (HR  0.45, 95% CI: 0.32–0.62,
p  0.001 at univariate analysis).
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To conclude, patients with advanced NSCLC may ben-
efit from third-line treatment. Most prognostic factors iden-
tified for first-line treatment are still relevant in a third-line
setting. Disease control after first- and second-line treatment
was the most reliable prognostic factor at the initiation of
third-line chemotherapy. As no prospective study has specifi-
cally been reported in this setting, this study provides relevant
data for routine practice and future prospective trials evaluating
third-line treatment strategies for advanced NSCLC.
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